ABSTRACT
PURPOSE: To examine the association of donor, recipient, and operative factors on graft dislocation after Descemet stripping automated endothelial keratoplasty (DSAEK) in the Cornea Preservation Time Study (CPTS) as well as the effects of graft dislocation and elevated IOP on graft success and endothelial cell density (ECD) 3 years postoperatively. DESIGN: Cohort study within a multi-center, double-masked, randomized clinical trial. METHODS: 1090 individuals (1330 study eyes), median age 70 years, undergoing DSAEK for Fuchs endothelial corneal dystrophy (94% of eyes) or pseudophakic or aphakic corneal edema (6% of eyes). Recipient eyes receiving donor corneal tissue randomized by preservation time (PT) of 0-7 days (N = 675) or 8-14 days (N = 655) were monitored for early or late graft failure through 3 years. Donor, recipient, operative, and postoperative parameters were recorded including graft dislocation (GD), partial detachment, and pre- and post-operative IOP. Pre- and postoperative central donor ECD were determined by a central image analysis reading center. Proportional hazards, mixed effects, and logistic regression models estimated risk ratios and (99% confidence intervals). RESULTS: Three independent predictive factors for GD were identified: a history of donor diabetes (odds ratio [OR]: 2.29 [1.30, 4.02]), increased pre-lamellar dissection central corneal thickness (OR: 1.13 [1.01, 1.27] per 25µ increase), and operative complications (OR: 2.97 [1.24, 7.11]). Among 104 (8%) eyes with GD, 30 (28.9%) developed primary donor or early failure and 5 (4.8%) developed late failure vs. 15 (1.2%; P < .001) and 29 (2.4%; P = .04), respectively, of 1226 eyes without GD. 24 (2%) of 1330 study eyes had early acutely elevated postoperative IOP that was associated with a higher risk of graft failure through 3 years (hazard ratio: 3.42 [1.01, 11.53]), but not with a lower mean 3-year ECD (mean difference 61 (-479, 601) cells/mm2, P = .77). History of elevated postoperative IOP beyond 1 month was not significantly associated with 3-year graft success or ECD. CONCLUSIONS: Donor diabetes, increased donor corneal thickness, and intraoperative complications were associated with an increased risk of GD. Early acutely elevated postoperative IOP and GD significantly increased the risk for graft failure following DSAEK.
Subject(s)
Cornea/pathology , Corneal Edema/surgery , Descemet Stripping Endothelial Keratoplasty/methods , Fuchs' Endothelial Dystrophy/surgery , Graft Rejection/prevention & control , Intraocular Pressure/physiology , Organ Preservation/methods , Adult , Aged , Aged, 80 and over , Cell Count , Corneal Edema/diagnosis , Double-Blind Method , Female , Follow-Up Studies , Fuchs' Endothelial Dystrophy/diagnosis , Graft Rejection/diagnosis , Graft Survival , Humans , Male , Middle Aged , Prospective Studies , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
PURPOSE: To describe a patient who developed Aureobasidium pullulans keratitis following refractive laser epithelial keratomileusis (LASEK). METHODS: A 52-year-old woman was referred to a tertiary care center 1 month after LASEK for treatment of a corneal ulcer that was unresponsive to conventional therapy. Mycology culture and fungal stain identified Aureobasidium as the infectious organism. RESULTS: The infection responded well to treatment with topical natamycin and systemic itraconazole. CONCLUSIONS: Treatment with topical natamycin and systemic itraconazole is effective against Aureobasidium pullulans keratitis.
Subject(s)
Ascomycota/isolation & purification , Corneal Ulcer/microbiology , Eye Infections, Fungal/microbiology , Keratectomy, Subepithelial, Laser-Assisted , Mycoses/microbiology , Postoperative Complications , Administration, Topical , Antifungal Agents/therapeutic use , Corneal Ulcer/diagnosis , Corneal Ulcer/drug therapy , Drug Therapy, Combination , Eye Infections, Fungal/diagnosis , Eye Infections, Fungal/drug therapy , Female , Humans , Itraconazole/therapeutic use , Middle Aged , Mycoses/diagnosis , Mycoses/drug therapy , Natamycin/therapeutic useABSTRACT
BACKGROUND: Mucous membrane pemphigoid (MMP), also known as cicatricial pemphigoid, is a serious, autoimmune, blistering disorder that can result in blindness and other complications as a result of scarring of the mucous membranes. Effective treatment modalities are often toxic. Herein, we describe a novel therapeutic approach that is based on 2 reports in the literature of the successful use of etanercept to treat MMP. OBSERVATIONS: Three patients with MMP were treated with subcutaneous injections of 25 mg of etanercept twice weekly. All 3 patients had oral mucosal involvement, and 1 had severe, recalcitrant, ocular disease. Oral mucosal disease improved in all 3 patients. The patient with ocular involvement experienced stabilization of progression. CONCLUSIONS: Effective treatment modalities for MMP are often toxic. Etanercept may be an effective treatment option for MMP of the oral and ocular mucous membranes. This therapy should be considered as an alternative treatment option for patients who would require other aggressive systemic treatments, such as cyclophosphamide, corticosteroids, azathioprine sodium, and intravenous immunoglobulin.
